Summary Philogen SpA (Philogen) is a biotechnology company that develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company’s pipeline products comprise darleukin, teleukin, fibromun, radretumab, dekavil and tetravil. Its technologies comprise DNA-encoded chemical libraries, antibody drug conjugates, immunocytokines, and antibody libraries, discovery of vascular targets, vascular targeting and easy iodine technology. Philogen develops drugs for treatment of severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company also provides clinical development programs for the treatment of cancer and of chronic diseases. Philogen is headquartered in Siena, Italy. Philogen SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in... Research Beam Model: Research Beam Product ID: 2637709 250 USD New
Philogen SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Philogen SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : October   2017
  • Pages : 21
  • Publisher : GlobalData
 
 
 
Summary

Philogen SpA (Philogen) is a biotechnology company that develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company’s pipeline products comprise darleukin, teleukin, fibromun, radretumab, dekavil and tetravil. Its technologies comprise DNA-encoded chemical libraries, antibody drug conjugates, immunocytokines, and antibody libraries, discovery of vascular targets, vascular targeting and easy iodine technology. Philogen develops drugs for treatment of severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company also provides clinical development programs for the treatment of cancer and of chronic diseases. Philogen is headquartered in Siena, Italy.

Philogen SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Philogen SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Philogen SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Philogen SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Philogen SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Philogen SpA, Medical Devices Deals, 2011 to YTD 2017 9
Philogen SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Philogen SpA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Philogen Enters into Co-Development Agreement with Janssen Biotech 11
Philogen Enters into R&D Agreement with AbbVie 12
Boehringer Ingelheim and Philogen Enter into Partnership 13
Licensing Agreements 14
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 14
Philogen Exercises Option for Licensing Agreement with Pfizer 15
Philogen Enters Into Licensing Agreement With Pfizer For Dekavil 16
Equity Offering 17
Philogen Withdraws IPO 17
Philogen SpA - Key Competitors 18
Philogen SpA - Key Employees 19
Philogen SpA - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List of Tables
Philogen SpA, Pharmaceuticals & Healthcare, Key Facts 2
Philogen SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Philogen SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Philogen SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Philogen SpA, Deals By Therapy Area, 2011 to YTD 2017 8
Philogen SpA, Medical Devices Deals, 2011 to YTD 2017 9
Philogen SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Philogen Enters into Co-Development Agreement with Janssen Biotech 11
Philogen Enters into R&D Agreement with AbbVie 12
Boehringer Ingelheim and Philogen Enter into Partnership 13
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 14
Philogen Exercises Option for Licensing Agreement with Pfizer 15
Philogen Enters Into Licensing Agreement With Pfizer For Dekavil 16
Philogen Withdraws IPO 17
Philogen SpA, Key Competitors 18
Philogen SpA, Key Employees 19
Philogen SpA, Other Locations 20
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter